| Dr Stephen Brett Marko, MD | |
|
1 Elliot Way, Manchester, NH 03103-3502 | |
| (603) 663-2710 | |
| Not Available |
| Full Name | Dr Stephen Brett Marko |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 10 Years |
| Location | 1 Elliot Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265843718 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20652 (New Hampshire) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 20652 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elliot Professional Services | 6103727920 | 304 |
News Archive
MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.
California has become the first state to ban the use for minors of disputed therapies to "overcome" homosexuality, a step hailed by gay rights groups across the country that say the therapies have caused dangerous emotional harm to gay and lesbian teenagers.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
The dream of personalized medicine - in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile - may be on the verge of being expanded beyond the wealthiest of nations with state-of-the-art clinics.
› Verified 3 days ago
| Entity Name | Elliot Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285627935 PECOS PAC ID: 6103727920 Enrollment ID: O20040115000634 |
News Archive
MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.
California has become the first state to ban the use for minors of disputed therapies to "overcome" homosexuality, a step hailed by gay rights groups across the country that say the therapies have caused dangerous emotional harm to gay and lesbian teenagers.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
The dream of personalized medicine - in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile - may be on the verge of being expanded beyond the wealthiest of nations with state-of-the-art clinics.
› Verified 3 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.
California has become the first state to ban the use for minors of disputed therapies to "overcome" homosexuality, a step hailed by gay rights groups across the country that say the therapies have caused dangerous emotional harm to gay and lesbian teenagers.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
The dream of personalized medicine - in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile - may be on the verge of being expanded beyond the wealthiest of nations with state-of-the-art clinics.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Brett Marko, MD 1 Elliot Way, Manchester, NH 03103-3502 Ph: (603) 663-2710 | Dr Stephen Brett Marko, MD 1 Elliot Way, Manchester, NH 03103-3502 Ph: (603) 663-2710 |
News Archive
MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.
California has become the first state to ban the use for minors of disputed therapies to "overcome" homosexuality, a step hailed by gay rights groups across the country that say the therapies have caused dangerous emotional harm to gay and lesbian teenagers.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
The dream of personalized medicine - in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile - may be on the verge of being expanded beyond the wealthiest of nations with state-of-the-art clinics.
› Verified 3 days ago
Jenny Lin, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Dr. Douglas F. Marks Jr., M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 87 Mcgregor St, Ste 4100, Manchester, NH 03102 Phone: 603-695-2500 Fax: 603-695-2647 | |
Dr. Jose E. Lozano, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester Va, Manchester, NH 03104 Phone: 603-624-4366 | |
Frances Jensen, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 456 Union St, Manchester, NH 03103 Phone: 866-679-0381 | |
Dr. Victor Gordan, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-626-6559 | |
Dr. Peter Wilson Shaw, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Mcgregor St # Stb, Manchester, NH 03102 Phone: 603-663-6350 | |
Dr. Goran Broketa, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-629-3217 |